Key takeaways
Erleada (apalutamide) and Xtandi (enzalutamide) are both medications that treat certain types of prostate cancer. They work by blocking testosterone, which helps slow or stop the growth of prostate cancer. Both medications are taken orally once a day. But Erleada is specifically approved for metastatic hormone-sensitive and non-metastatic castration-resistant prostate cancer, while Xtandi is approved for castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and non-metastatic hormone-sensitive prostate cancer with a high risk of spreading. Common side effects of Erleada include tiredness, joint pain, and rash, while Xtandi may cause weakness, back pain, and hot flashes. Additionally, Xtandi has more drug interactions, such as with grapefruit.
